Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

NCT03939026 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Large B Cell Lymphoma
Relapsed/Refractory Follicular Lymphoma

Interventions

GENETIC: ALLO-501
BIOLOGICAL: ALLO-647
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Allogene Therapeutics